Background and Aim: Transmural inflammation in Crohn's disease [CD] 
Introduction
The relapsing and remitting character of Crohn's disease [CD] results in accumulating damage to the bowel wall. In consequence, the natural history of CD is marked by a progressive evolution to fibrotic changes in the bowel wall, which ultimately may lead to strictures. [1] [2] [3] The presence of stricturing disease is associated with a 4-5-fold higher need for surgical resection over time. 4 Although efficacious treatments capable of inducing mucosal healing exist, surgery is still necessary in many patients. [5] [6] [7] [8] [9] Furthermore, about half of the patients require surgery within 10 years after diagnosis. 6 Cross-sectional imaging with computed tomography [CT] and magnetic resonance [MR] enterogaphy are the best techniques to assess stricturing disease in CD. 10 Besides, cross-sectional imaging provides information not only on luminal disease activity but also on extra-intestinal involvement and disease complications. Although clinical and genetic risk factors for complicated CD are described, [11] [12] [13] [14] [15] [16] still only few data exist on the predictors for surgery in patients with stricturing CD. 15 The aim of this study was to identify risk factors in patients with stricturing CD, which are associated with a need for subsequent surgery. By stratifying risk factors for surgery at diagnosis, an optimal treatment plan can be established which may guide decision-aking towards medical or surgical treatment.
Materials and Methods

Design and patients
This was a retrospective cohort study in a tertiary referral centre. Data were collected through a search in the electronic medical database of the University Hospitals Leuven, Belgium. We identified all patients with histologically proven Crohn's disease, who had a CT and/or MR enterography of the abdomen between April 2006 and December 2014. Last follow-up was in November 2015. All patients had consented for their data to be analysed through the VLECC Biobank [Vlaamse Erfelijkheidsstudie Crohn en Colitis Ulcerosa, or Flemish Study for Genetics Research on Crohn's Disease and Ulcerative Colitis] which was approved by the local ethics review board [B322201213950/S53684].
All CT and MR imaging was evaluated for the presence of ileal stricturing and/or penetrating CD complications according to the Montreal classification [ Table 1 ]. 17, 18 Since no generally accepted definition for an ileal stricture exists in this classification, 17, 19 stricturing disease was defined as at least 50% of luminal narrowing in the presence of radiological signs of CD as described by the radiologist. Also for prestenotic dilation, no generally accepted definition exists. In our department, prestenotic dilation is defined as relative luminal distention of the bowel in comparison with a non-affected segment.
Penetrating complications were defined as abscess, phlegmon or fistula. Only patients with documented stricturing CD on imaging were retained. The imaging data collected in the study were based on the first imaging that documented the stricturing ileal disease. In patients having subsequent cross-sectional imaging after the index imaging, changes in the imaging data were not retained.
Demographic data and disease characteristics were collected by retrospective review of the electronic medical charts of the patients. The data included: date of birth, gender, smoking status, age at diagnosis of CD, age at diagnosis of stricturing disease behaviour, C-reactive protein [CRP] 20 The phenotypic and radiological characteristics of stricturing CD were collected. These included the interval between diagnosis of CD and diagnosis of stricturing complication, length of stenosis, presence of prestenotic dilation on cross-sectional imaging [as assessed by the radiologist], abscess, phlegmon, ileal fistula, type of surgery, need for endoscopic balloon dilation, hospitalization for stricturing CD, cancer in stricturing CD, impassable stricture at endoscopy, complications after surgery for stricturing CD, and death. The clinical signs at diagnosis of ileal stricturing CD were defined as follows: asymptomatic = incidental finding of stricturing CD without correlated CD symptoms; subobstruction = intermittent cramping pain with abdominal distention; obstruction = complete blockage of the intestinal tract with vomiting, abdominal distension, and cramping pain.
Results were then validated in an independent cohort of patients with CD being followed at the large peripheral non-academic hospital. For this we used the same methodology as used in the original cohort. All patients with CD who had a CT and/or MR enterography between January 2011 and December 2012 in the Imelda General Hospital, Bonheiden, Belgium, were evaluated for the presence of stricturing CD. Last follow-up was on June 30, 2017 for this cohort. The only missing variable was the CARD15/NOD2 mutation status, since genotyping for this CD-susceptibility gene has no clinical utility and therefore is not performed in general practice. We therefore evaluated the risk for surgery based on four risk factors derived from the first cohort: B3 Montreal class [ 
Results
Patient population
The . This is due to the shift from CT to MR over recent years in order to avoid ionizing radiation in IBD patients. Radiological signs of stricturing CD were detected in 486 examinations belonging to 359 patients. Of these patients, 244 had a at least one stricture localiz=sed in the ileum. In nine patients, the electronical medical records were incomplete. These patients were excluded from further analysis, resulting in a total of 235 patients in this series. Demographic data are summarised in Table 2a, 2b. A total of 41% of the patients already had had CD-related surgery before the diagnosis of stricturing CD in this observation period. The median interval between the previous IBD surgery and the diagnosis of a new stricturing complication was 8 Univariate analysis identified several factors significantly associated with the need for subsequent intestinal resection or strictureplasty [ Table 3 ]. These could be divided into clinical, imaging, and genetic factors. More precisely, clinical factors included presence of intestinal obstruction, previous/current anti-TNF use, and an elevated CRP. A cut-off of 11 mg/L was obtained based on a ROC analysis [see Supplementary Figure 1 , available as Supplementary data at ECCO-JCC online]. Also younger age at first documentation of stricturing CD was significantly associated with subsequent need for surgery. Imaging factors included prestenotic dilation, presence of abscesses and fistulas, and long strictures > 5 cm based on ROC analyses [see Supplementary Figure 2 , available as Supplementary data at ECCO-JCC online]. The generally accepted length of a stenosis that can be dilated endoscopically is 5 cm. 21 In line with this, an association was seen between the feasibility of endoscopic dilation and surgery. The presence of at least one risk allele for NOD2 rs2066844 was associated with surgery. of abscess or fistula was not entered since the factor 'coexisting Montreal class B3' was used. Due to the link between the length of the stricture and the feasibility of endoscopic balloon dilation, only the variable stenosis > 5 cm was used. Five factors remained significantly associated with the need for surgery over time [ Table 4 ].
The strongest association was seen with the presence of a prestenotic dilation on imaging. If the proximal ileal segment was dilated, this was associated with a 2.05-fold [95% CI 1. 
Impact of NOD2 variants in stricturing ileal CD
Further univariate analysis focusing on the impact of NOD2 genotype did not show any significant impact of the NOD2 status on the age of diagnosis of CD, the length of the stricture, or the speed of developing a primary stricture. The interval between the first documentation of the stricture on imaging and subsequent surgery was borderline significant [p = 0.05]. Figure 3 , available as Supplementary data at ECCO-JCC online]. The absolute risk for surgery was 34%, 68%, 81%, and 100% for the low, medium, high, and all risk groups, respectively. Only 13 patients had no risk factors; these patients had an absolute operative risk over time of 54%. Survival analysis looking at the time to surgery showed a separation of the lines already early during follow-up [ Figure 2a ]. Over time, the curves dissociated further [ Figure 2b ], resulting in a surgery-free survival of 77%, 38%, 19%, and 0% for the low, medium, high, and all risk groups, respectively, after 5 years. Apart from the clear difference between the absolute need for surgery over time, there was a 
Validation of the BACARDI risk model
For the validation cohort, we identified 116 cross-sectional imaging studies performed in 88 patients with CD. Of these, 27 patients had ileal stricturing disease. The median follow-up time after diagnosis of stricturing CD was 5.64 years ]. Survival analysis looking at the time to surgery showed a separation of the curves early during follow-up and continuing over time [ Figure 3 ]. This resulted in a surgery-free survival of 100%, 44%, and 0% for the low, medium and high risk groups, respectively, after 5 years 
Discussion
Based on our patient cohort and a long follow-up period, we could build a risk model─the BACARDI risk model─by using a wide range of demographic, clinical, biochemical, imaging, endoscopic, and genetic factors. This model refines the multidisciplinary approach of a complex patient with CD by integrating five factors: B3 Montreal class, Anti-TNF exposure, CARD15/NOD2 mutation [rs2066844], Dilation of the prestenotic segment, and Inflammation [CRP > 11 mg/L] at diagnosis of stricturing CD. We validated this risk stratification model in an independent cohort from a large peripheral nonacademic inflammatory bowel disease [IBD] centre incorporating the four clinically useful factors. Based on this, we feel this model is an additional tool in clinical decision making [ Figure 4 ]. This is important since the natural history of CD is marked by complications such as intestinal strictures 1,2 which may lead to repetitive surgeries, resulting in short bowel syndrome and malabsorption. Although the expanded therapeutic armamentarium makes it feasible to reach the goal of mucosal healing, with beneficial effects on the need for surgery, we cannot neglect the fact that 30-50% of patients will undergo surgery 10 years after CD diagnosis. [22] [23] [24] As a consequence, the European Crohn's and Colitis Organisation [ECCO] guidelines recommend resection of ileal stricturing segments in the absence of inflammation. 25 However, the presence of fibrosis does not exclude persistent inflammation, and vice versa. This wide variation in the type of stricturing ileal CD and the degree of persistent inflammation makes the implementation of the guidelines difficult. In contrast with Mao et al. our model also integrates asymptomatic patients and patients with previous surgery and associated penetrating complications. 15 We feel this is a strength, as it is the first risk model in stricturing ileal CD based on an integral real-life cohort. Futhermore, the validation in an independent non-academic cohort underscores the value of the model for clinical use even in the absence of knowledge on CARD15/NOD2 mutation status.
For patients in the 'low risk' group, we found a surgery-free survival after 5 years of 77%, which was confirmed in the validation cohort [100%] . Therefore the continuation of medical treatment is justifiable, certainly since not all patients were symptomatic. This approach was also suggested to be successful in the recent CREOLE study from the Groupe dʹÉtude Thérapeutique des Affections Inflammatoires du Tube Digestif [GETAID] 26 although only symptomatic patients were included. Bouhnik et al. evaluated the efficacy of adalimumab inpatients with CD presenting with a symptomatic small bowel stricture. In 64% of the patients, medical treatment with adalimumab was successful at Week 24, and at 3 years 30% were still on adalimumab without any endoscopic or surgical intervention. For the same reason a cautious approach is warranted in the 'medium risk' group, by optimising medical treatment and performing endoscopic dilation when indicated and re-evaluation after 1 year. In the 'high risk' group, surgery can only be postponed if there is a clear contraindication for surgery, because in this group the median time to surgery is only 2 months and the 5-year surgery-free survival is only 19% [0% in the validation cohort]. If CARD15/NOD2 mutations are present in patients having all risk factors, there is no reason to start or optimise ongoing medical therapy. Postponing surgery in this latter group will expose patients to further complicating disease and potential side effects of the medical treatment and/or more complicated surgery in the end.
To further optimise our model, a precise differentiation between inflammation and fibrosis on MR is needed. As documented by Rimola et al., contrast enhancement in MR can detect patterns of severe fibrosis, 27 but absolute cut-off values are lacking. Furthermore, the prediction of postoperative recurrence should be studied in view of the type of stricturing ileal CD. Data from Mount Sinai have shown that pure stricturing CD without coexisting penetrating behaviour has low postoperative recurrence rates, which could favour early surgery for this patient group. 28 As a link between NOD2 genotype and disease location and phenotype has been established in CD, 14, 16, 29 we looked at the influence of NOD2 genotype on the need for surgery in patients with ileal stricturing CD. We demonstrated a link between carriage of NOD2 rs2066844 and the need for surgery over time. Siederer et al. have previously documented an association between NOD2 rs2066847, 30 but this could not be confirmed in this cohort. Elevated CRP [cutoff = 11 mg/L] at diagnosis of stricturing CD was associated with a higher risk for surgery in our cohort. This can be a reflection of the severity of the disease, although patients with high CRP have more pronounced efficacy of anti-TNF in clinical trials. 31 Other data show that high CRP is predictive for non-response to anti-TNF, 32 making the patient more prone to surgery.
Our study has some shortcomings. First, it is a retrospective study and selection bias cannot be ruled out. We tried to overcome this by reviewing all patients who had cross-sectional abdominal imaging in our hospital. This is the preferential method for the diagnosis of stricturing CD complications in our centre. Second and also related to the retrospective approach, is the fact that it is unclear whether the factors in the risk model are real predictors of subsequent disease behaviour or indicators of physician preferences. However, the strength of this model is that it includes multiple factors and none of them is an absolute indication for surgery in our multidisciplinary team discussion. Furthermore, the validation of the model in an independent cohort confirmed its robustness. Third, the selection of patients was based on stricturing CD as described by the radiologist, but unfortunately no standardised radiological reporting was used. Furthermore, this selection of radiological images can be biased by the performance of the radiological technique [e.g. no oral contrast in case of complete intestinal obstruction, suboptimal timing of scanning with consequent incomplete distention]. Nevertheless, all abdominal CT and/or MR imaging is read by a team of three dedicated abdominal radiologists.
In conclusion, we found that two-thirds of patients with stricturing ileal CD need surgery over time. A risk stratification based on the BACARDI risk model [B3 Montreal class, Anti-TNF exposure, CARD15/NOD2 mutation [rs2066844], Dilation of the prestenotic segment, and Inflammation [CRP > 11 mg/L] at diagnosis of stricturing CD] improves the therapeutic decision in patients with stricturing ileal CD. Based on this risk model, guidance is given on the timing and indication for surgery in patients with stricturing ileal CD. This risk model now needs prospective validation.
